Description & Objectives
This conference is targeted towards all health-care providers across the U.S. who treat patients with colorectal cancer, including physicians, allied health professionals and residents. The conference is specifically intended for the following specialties: gastroenterology, colorectal and general surgery, medical oncology and family medicine.
Across all races in the United States, colorectal cancer is the third most prevalent cancer and is the second leading cancer-related cause of death worldwide. Prevention and early detection are the keys to reducing death due to this life-threatening disease. This is dependent upon early and regular screening to facilitate the detection and removal of precancerous colorectal polyps and by treating the cancer in its early stages. There is a 5 year survival rate of 90% when colorectal cancer is detected early, but because screening rates are low, less than 40% of colorectal cancers are found early. If everyone over 50 years of age was screened regularly, deaths from this cancer could be reduced by 60%, according to Centers for Disease Control and Prevention. Early detection can greatly increase the chance of treatment being successful. Mayo Clinic researchers concluded that “Colorectal Cancer, the second most common cause of cancer-related mortality worldwide, is preventable with effective screening and removal of precursor lesions.”(1)
Because screening rates are low, the need for physicians to be up-to-date in not only screening methods, but also ground breaking procedures, adjuvant and neoadjuvant therapies and drug treatments of colorectal cancer is critical to the survival rate. Although surgery is still the most common treatment for all stages of colorectal cancer, it is vital that physicians and patients are aware of the multitude of options and combinations of treatments available. There have been many recent developments in the treatment of colorectal cancer. This course will educate providers on the innovations in systemic therapy, management of chemotherapy, quality assessment in managing rectal cancer care, and new surgical techniques being utilized in the field, as well as screening approaches.
1. Colorectal Research; New Findings from Mayo Clinic Describe Advances in Colorectal Research, Life Science Weekly, Atlanta: Mar 6, 2012, pg. 1558
At the conclusion of the symposium, the participant will provide better patient care through an increased ability to:
- State the toxicities and efficacy of newly approved agents for metastatic colorectal cancer and identify options for sequencing treatments with targeted therapies in metastatic colorectal cancer
- Review the current state of treatment for colorectal cancer (CRC), current biomarker knowledge and future plans for biomarker discovery
- State diet and lifestyle factors after a diagnosis of colorectal cancer, explain the limitation of current data on CRC survivorship and identify opportunities to further the field
- Discuss and clarify colorectal cancer treatment, therapies and CRC survivorship
- Explain new opportunities for endoscopy in colon cancer detection and recognize the option of endoscopic resection of even very large, non-cancerous polyps instead of surgery
- Describe the pros and cons of enteral stenting and other ablative techniques for non-surgical palliation of bleeding or obstructing colon lesions
- Define the proper staging evaluation for patients with rectal cancer, identify appropriate organ sparing techniques for early rectal neoplasia and compare outcomes between radical surgery and organ sparing surgery for rectal neoplasia
- Explain current techniques and indications for the use of cytoreductive surgery and results of HIPEC treatment in appendiceal neoplasms
- State and clarify endoscopic therapies, organ sparing techniques and appendiceal neoplasm surgery and treatment
- Discuss attendees’ cases in a multidisciplinary forum, reinforce concepts, clarify treatment options and identify strategies and techniques used by the experts